NFE2L2 and renal cell carcinoma: Some of these molecules and pathways, including NRF2 signaling, which is the most significantly activated pathway in Caki-2 versus Caki-1 cells, could serve as potential diagnostic and prognostic biomarkers and therapeutic targets for RCC subtypes.